{"id":"amor-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K/AKT pathway, AMOR-1 aims to reduce tumor growth and proliferation. This mechanism is being explored for its potential in treating various types of cancer.","oneSentence":"AMOR-1 is a small molecule that targets the PI3K/AKT signaling pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:56:28.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06547151","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults","status":"RECRUITING","sponsor":"Amorphical Ltd.","startDate":"2024-12-15","conditions":"Hypoparathyroidism","enrollment":81},{"nctId":"NCT02864784","phase":"PHASE1","title":"Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC","status":"WITHDRAWN","sponsor":"Amorphical Ltd.","startDate":"2022-06","conditions":"Castrate Resistant Prostate Cancer With Bone Metastasis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMOR-1","genericName":"AMOR-1","companyName":"Amorphical Ltd.","companyId":"amorphical-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMOR-1 is a small molecule that targets the PI3K/AKT signaling pathway. Used for Phase 2 clinical trials for metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}